Año: 2021
Journal Impact Factor (JIF): 12.4850
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| ONCOLOGY | SCIE | 25/245 | Q1 | T1 | D1 |
| IMMUNOLOGY | SCIE | 18/162 | Q1 | T1 | D2 |
Año: 2021
Journal Citation Indicator (JCI): 1,970
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| IMMUNOLOGY | 14/178 | Q1 | T1 | D1 | 92,42 |
| ONCOLOGY | 22/318 | Q1 | T1 | D1 | 93,24 |
Año:
2021
CiteScore:
14,300
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Molecular Medicine | 11/167 | Q1 | T1 | D1 |
| Oncology | 25/360 | Q1 | T1 | D1 |
| Pharmacology | 11/303 | Q1 | T1 | D1 |
| Cancer Research | 22/210 | Q1 | T1 | D2 |
| Immunology | 26/213 | Q1 | T1 | D2 |
| Immunology and Allergy | 21/200 | Q1 | T1 | D2 |
SJR año:
2021
Factor de Impacto:
3,450
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Cancer Research | 17/238 | Q1 | T1 | D1 |
| Immunology | 16/235 | Q1 | T1 | D1 |
| Immunology and Allergy | 12/224 | Q1 | T1 | D1 |
| Molecular Medicine | 7/180 | Q1 | T1 | D1 |
| Oncology | 20/404 | Q1 | T1 | D1 |
| Pharmacology | 5/327 | Q1 | T1 | D1 |
| Agencia | Código de Proyecto |
|---|---|
| Bristol Myers Squibb | 238 |
| ONO Pharmaceutical | - |
| # | Autor | Afiliación |
|---|---|---|
| 1 | Mandala, Mario | Università degli Studi di Perugia (Italy) |
| 2 | Larkin, James | Royal Marsden NHS Foundation Trust (United Kingdom) |
| 3 | Ascierto, Paolo Antonio | Istituto Nazionale Tumori IRCCS - Fondazione G Pascale, Napoli (Italy) |
| 4 | Del Vecchio, Michele | Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy) |
| 5 | Gogas, Helen | University of Athens Medical School (Greece) |
| 6 | Cowey, C. Lance | Baylor Charles A. Sammons Cancer Center (United States) |
| 7 | Arance, Ana | Hospital Clinic Barcelona (Spain) |
| 8 | Dalle, Stéphane | CHU de Lyon (France) |
| 9 | Schenker, Michael | Sf. Nectarie Oncology Medical Center (Romania) |
| 10 | Grob, Jean Jacques | Aix Marseille Université (France) |
| 11 | Chiarion-Sileni, Vanna | Istituto Oncologico Veneto IOV - IRCCS (Italy) |
| 12 | Marquez, Ivan | Hospital General Universitario Gregorio Marañon (Spain) |
| 13 | Butler, Marcus O. | Princess Margaret Cancer Centre (Canada) |
| 14 | Di Giacomo, Anna Maria | Azienda Ospedaliera Universitaria Senese (Italy) |
| 15 | Lutzky, Jose | Mount Sinai Medical Center Miami Beach (United States) |
| 16 | Cruz-Merino, Luis de la | Universidad de Sevilla; Hospital Universitario Virgen Macarena (Spain) |
| 17 | Atkinson, Victoria | The University of Queensland (Australia) |
| 18 | Arenberger, Petr | Fakultní nemocnice Královské Vinohrady (Czech Republic) |
| 19 | Hill, Andrew | Tasman Oncology Research Ltd (Australia) |
| 20 | Fecher, Leslie | University of Michigan Rogel Cancer Center (United States) |
| 21 | Millward, Michael | University of Western Australia (Australia) |
| 22 | Khushalani, Nikhil I. | Moffitt Cancer Center (United States) |
| 23 | De Pril, Veerle | Bristol-Myers Squibb (United States) |
| 24 | Lobo, Maurice | Bristol-Myers Squibb (United States) |
| 25 | NYU Langone Health (United States) |